ARMP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide...

Stats
Dzisiejszy wolumen	6 133.00
Średni wolumen	15 935.00
Kapitalizacja rynkowa	90.01M
EPS	$0 ( 2024-03-21 )
Następna data zysków	( $-0.280 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.300
ATR14	$0.0460 (1.77%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Patti Joseph M	Buy	54 343	Stock Options (Right to Buy)
2024-03-14	Patti Joseph M	Buy	39 666	Stock Options (Right to Buy)
2024-03-14	Kramer Robin	Buy	54 343	Stock Options (Right to Buy)
2024-03-14	Kramer Robin	Buy	39 666	Stock Options (Right to Buy)
2024-03-14	Peterson Todd C.	Buy	54 343	Stock Options (Right to Buy)

INSIDER POWER
98.47
Last 92 transactions
Buy: 43 961 909 \| Sell: 1 182 185

Armata Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Armata Pharmaceuticals Finanse

Annual	2023
Przychody:	$4.53M
Zysk brutto:	$3.56M (78.54 %)
EPS:	$-1.910

FY	2023
Przychody:	$4.53M
Zysk brutto:	$3.56M (78.54 %)
EPS:	$-1.910

FY	2022
Przychody:	$5.51M
Zysk brutto:	$4.62M (83.81 %)
EPS:	$-1.080

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.960

Financial Reports:

No articles found.

Armata Pharmaceuticals

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Aktualne aktualizacje dla Armata Pharmaceuticals [ARMP]

Upcoming Earnings Alert